As for patients with EML4-ALK(+) NSCLC, with crizotinib resistant mutations, NPM-ALK(+) ALCL patients could benefit in the years to come from second- and third-generation ALK inhibitors alone or in combination with inhibitors of key downstream cell signaling pathways or key regulators of ALK tyrosine kinase activity. This evidence concerns the gene ALK and anaplastic large cell lymphoma.